Horizon Technology Finance Corp. (HRZN) - Q3 2020 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2020. Horizon Technology Finance Corp. is an externally managed, closed-end, non-diversified business development company (BDC) and regulated investment company (RIC). The Company primarily makes secured debt investments to development-stage companies in the technology, life science, healthcare information and services, and sustainability industries.
Key Financial Metrics
| Metric | Q3 2020 (3 Months) | YTD 2020 (9 Months) | YTD 2019 (9 Months) |
|---|---|---|---|
| Total Investment Income | $12.3 million | $36.0 million | $30.2 million |
| Net Investment Income | $5.9 million | $16.8 million | $14.0 million |
| Net Realized Gain/Loss | $1.2 million (Gain) | $3.9 million (Gain) | $(3.9) million (Loss) |
| Net Unrealized Gain/Loss | $(10.3) million | $(16.8) million | $2.6 million |
| Net Increase/(Decrease) in Net Assets | $(3.3) million | $4.0 million | $12.8 million |
| Net Asset Value (NAV) per Share | $11.17 | $11.17 | $11.67 |
| Total Borrowings Outstanding | $163.7 million | $163.7 million | $152.1 million |
| Cash and Cash Equivalents | $56.9 million | $56.9 million | $16.3 million |
Material Changes vs. Prior Period
- Portfolio Valuation: The Company recorded a net unrealized depreciation of $10.3 million for the quarter and $16.8 million year-to-date, primarily driven by mark-downs on specific debt investments. This contrasts with the prior year, which saw net unrealized appreciation.
- Investment Income: Total investment income increased 8.4% quarter-over-quarter and 19.3% year-over-year, driven by a larger average debt investment portfolio size, partially offset by lower LIBOR rates.
- Realized Gains: The Company realized a net gain of $1.2 million in Q3 2020, compared to a net loss of $0.4 million in Q3 2019. Year-to-date realized gains were $3.9 million, a significant improvement over the $3.9 million loss in the same period in 2019.
- Consolidation of HSLFI: On April 21, 2020, the Company purchased all interests in Horizon Secured Loan Fund I LLC (HSLFI), consolidating its assets and liabilities. This transaction removed the "Equity interest in HSLFI" line item from the balance sheet as of September 30, 2020.
- Liquidity: Cash and cash equivalents increased significantly to $56.9 million from $16.3 million at year-end 2019, bolstered by equity issuances and principal repayments.
Guidance, Outlook, and Risks
- COVID-19 Impact: Management highlights that the pandemic continues to create economic disruptions, affecting portfolio company operations and potentially leading to increased defaults, refinancing difficulties, and valuation volatility.
- Asset Quality: As of September 30, 2020, five debt investments were rated "1" (deteriorating credit quality/high risk of loss) with a fair value of $19.4 million, up from two such investments at year-end 2019.
- Subsequent Event: Following the filing, the Company acquired the assets of Espero BioPharma, Inc. via a credit bid of $7.0 million after the portfolio company assigned assets to an assignment estate.
- Capital Markets: The Company maintains an At-The-Market (ATM) equity distribution agreement with $87.0 million remaining available for issuance. No stock repurchases were made during the quarter.
- Interest Rate Risk: The Company is exposed to interest rate fluctuations as most debt investments bear floating rates. A 100 basis point increase in rates would increase net assets by approximately $0.4 million annually.
Investor Verification Checklist
- Non-Accrual Status: Verify the specific portfolio companies placed on non-accrual status (four as of Sept 30, 2020) and the associated fair value write-downs.
- Espero BioPharma Acquisition: Review the terms and valuation of the subsequent asset acquisition of Espero BioPharma to understand the impact on future portfolio composition.
- Unfunded Commitments: Note the $80.9 million in unfunded commitments to extend credit, which represents a significant off-balance-sheet obligation.
- Debt Maturities: Review the maturity schedule of the $163.7 million in borrowings, including the Key Facility (maturing 2023) and Asset-Backed Notes (maturing 2027).
- NAV vs. Market Price: Compare the reported NAV of $11.17 against the market trading price to assess the discount/premium status of the stock.